T

    Tenax Therapeutics Inc (TENX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.13
    -0.06 (-2.74%)

    Market Cap: $79.71M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    -5.12%
    Streak
    9 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.39 - $-0.33
    7 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.41-12.5%
    60d ago$-0.41-12.5%
    30d ago$-0.38-6.0%
    7d ago$-0.38-6.5%
    Current$-0.36
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.33
    Range$-0.63 - $-0.03
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.33---
    Sep 26EST
    		-$-0.36---
    Jun 26
    Reported Jul 31
    		$-0.35$-0.38+7.89%Beat-29.6%
    Mar 26
    Reported May 12
    		$-0.35$-0.40+12.50%Beat-25.0%
    Dec 25
    Reported Mar 10
    		$-0.38$-0.41+8.43%Beat-111.1%
    Sep 25
    Reported Nov 12
    		$-0.40N/A+64.29%Beat-110.5%
    Jun 25
    Reported Aug 13
    		$-0.27$-0.45+40.00%Beat+85.2%
    Mar 25
    Reported May 14
    		$-0.28$-0.41+31.71%Beat+91.0%
    Dec 24
    Reported Mar 25
    		$-0.18N/A+57.65%Beat+98.6%
    Sep 24
    Reported Nov 13
    		$-0.19N/A+86.13%Beat+97.0%
    Jun 24
    Reported Aug 13
    		$-1.83$-2.25+18.67%Beat+54.3%
    Mar 24
    Reported May 14
    		$-3.12$-3.06-1.96%Miss+74.0%
    Dec 23
    Reported Mar 28
    		$-12.98$-8.14-59.46%Miss-650.3%
    Sep 23
    Reported Nov 13
    		$-6.40$-7.20+11.11%Beat+96.4%
    Jun 23
    Reported Aug 14
    		$-4.00$-5.60+28.57%Beat+97.7%
    Mar 23
    Reported May 15
    		$-12.00N/A+59.46%Beat+93.2%
    Dec 22
    Reported Mar 30
    		$-1.73$-2.28+24.12%Beat-116.2%
    Sep 22
    Reported Nov 10
    		$-176.00$-176.00+0.00%Beat+26.7%
    Jun 22
    Reported Aug 11
    		$-176.00$-144.00-22.22%Miss-10.0%
    Mar 22
    Reported May 16
    		$-176.00$-144.00-22.22%Miss-436.6%
    Dec 21
    Reported Mar 31
    		$-0.80N/A+75.00%Beat+99.9%
    Sep 21
    Reported Nov 16
    		$-240.00$-208.00-15.38%Miss+16.7%
    Jun 21
    Reported Aug 16
    		$-160.00$-256.00+37.50%Beat+56.5%
    Mar 21
    Reported May 17
    		$-32.80$-4.20-680.95%Miss+94.6%
    Dec 20
    Reported Mar 31
    		$-960.00$-288.00-233.33%Miss-11607.3%
    Sep 20
    Reported Nov 16
    		$-288.00$-256.00-12.50%Miss+45.5%
    Jun 20
    Reported Aug 17
    		$-368.00$-320.00-15.00%Miss+17.9%
    Mar 20
    Reported May 15
    		$-608.00$-304.00-100.00%Miss-15.2%
    Dec 19
    Reported Mar 30
    		$-8.20$-12.10+32.23%Beat-801.1%
    Sep 19
    Reported Nov 14
    		$-528.00$-496.00-6.45%Miss+68.6%
    Jun 19
    Reported Aug 14
    		$-448.00$-576.00+22.22%Beat+78.3%
    Mar 19
    Reported Apr 1
    		$-528.00$-544.00+2.94%Beat+60.2%
    Dec 18
    Reported Mar 31
    		$-0.91N/A+85.32%Beat+3.7%
    Sep 18
    Reported Nov 14
    		$-1680.00$-2336.00+28.08%Beat-31.3%
    Jun 18
    Reported Aug 14
    		$-2064.00$-1600.00-29.00%Miss+41.4%
    Mar 18
    Reported Apr 2
    		$-1328.00$-1712.00+22.43%Beat+65.4%
    Dec 17
    Reported Mar 20
    		$-0.94$-1.60+40.94%Beat-101.8%
    Sep 17
    Reported Nov 9
    		$-1280.00$-2240.00+42.86%Beat+73.3%
    Jun 17
    Reported Aug 9
    		$-3520.00$-2880.00-22.22%Miss-
    Mar 17
    Reported May 10
    		$-3840.00$-3200.00-20.00%Miss-
    Dec 16
    Reported Mar 21
    		$52.00$-58.00+189.66%Beat-
    Sep 16
    Reported Nov 10
    		$-4800.00$-5120.00+6.25%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.44EV/EBITDA-0.14x
    Price/FCF-2.35xFCF Yield-42.48%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-59.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio15.07xQuick Ratio15.07x
    Trading Statistics
    Beta0.93Avg Volume9.73M
    52-Week High$19.4052-Week Low$1.31

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.95
    SMA 20$4.79
    SMA 50$10.91
    SMA 200$12.02
    EMA 10$2.60
    EMA 20$4.72
    EMA 50$8.60
    EMA 200$10.80

    MACD

    Line: -2.88Signal: -3.05Hist: 0.17

    ADX

    ADX: 44.1+DI: 15.7-DI: 45.5

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down44.0
    PSAR$5.77

    Bollinger Bands

    Upper Band$15.23
    Lower Band$-5.66
    %B Position43646%(Upper)
    Band Width0.37

    RSI (14-Day)

    Oversold
    24.3

    Momentum Oscillators

    Stoch %K51.6
    Stoch %D29.5
    Williams %R-30.0
    ROC (10d)18.3%
    Momentum0.33
    CCI (20d)-39.7
    MFI (14d)66.9

    Volatility Measures

    ATR (14d)$0.84(39.6%)
    StdDev (20d)5.22
    Hist Vol353.4%(High)

    Volume Flow

    VWAP$2.18
    OBV7.2M
    AD Line-35.6M
    CMF (20d)-0.184

    Volume Metrics

    Avg Vol (20d)10.5M
    Vol Ratio0.3x(Low)
    VWMA (20d)$2.24

    Pivot Points

    R3$2.38
    R2$2.30
    R1$2.25
    Pivot Point$2.17
    S1$2.12
    S2$2.04
    S3$1.99

    Advanced Oscillators

    TSI-54.47
    Ultimate Osc46.5
    KST-815.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2,000$0$0$0$5,790$0
    Cost of RevenueN/AN/AN/AN/AN/AN/A$1,000N/A$1,000N/A$4,670$1,000
    Gross ProfitN/AN/AN/AN/AN/AN/A$1,000N/A$-1,000N/A$-4,670$-1,000
    Operating Expenses$18.78M$16.57M$16.45M$16.81M$11.79M$11.34M$7.29M$-4,618,881$3.67M$3.91M$3.34M$-2,117,379
    R&D$12.85M$11.54M$10.54M$10.33M$6.12M$5.68M$4.59M$3.11M$2.33M$2.68M$1.70M$1.07M
    SG&A$5.93M$5.03M$5.91M$6.48M$5.67M$5.66M$2.70M$1.51M$1.34M$1.23M$1.64M$1.05M
    Operating Income$-18,784,000$-16,573,000$-16,449,000$-16,806,000$-11,792,000$-11,338,000$-7,294,772$4.62M$-3,671,000$-3,909,000$-3,340,937$2.12M
    Interest Income$981,000$861,000$918,000$1.02M$954,000$930,000$1.03M$664,724$104,883$118,000$0$150,741
    Interest Expense$0$0$0$0$0$0$464$6,312$9,189$7,963$2,154$5,337
    Income Before Tax$-17,803,000$-15,716,000$-15,540,000$-15,804,000$-10,847,000$-10,408,000$-6,267,018$-3,960,469$-3,575,000$-3,799,000$-3,225,599$-1,971,975
    Income Tax Expense$0$0$0$0$0$0$0$3.96M$0$107,597$1.13M$-4,084,017
    Net Income$-17,803,000$-15,716,000$-15,540,000$-15,804,000$-10,847,000$-10,408,000$-6,267,018$-3,960,469$-3,575,000$-3,799,000$-3,225,599$-1,971,975
    EBITDA$-18,784,000$-15,716,000$-15,540,000$-15,804,000$-10,847,000$-10,408,000$-6,267,019$-3,954,157$-3,566,000$-3,791,000$-3,218,777$-1,965,669
    EBITN/AN/AN/AN/A$-11,792,000$-11,338,000$-6,312,018$-3,952,265$-3,566,488$-3,792,769$-3,223,447$-1,966,638
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TENX

    News

    Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

    Tenax Therapeutics, Inc. announced that its President & Chief Executive Officer, Chris Giordano, will present at the 2026 Cantor Global Healthcare Conference on September 9, 2026. The presentation will be available via webcast on the company's investor relations webpage. Tenax Therapeutics is a Phase 3 pharmaceutical company focused on developing cardiopulmonary therapies, holding global rights to levosimendan for PH-HFpEF treatment.

    Investing News Network•9/1/26•
    Neutral

    Tenax Therapeutics discloses ADAR1 Capital Management as beneficial owner in Form 3 filing

    Tenax Therapeutics has disclosed in a Form 3 filing that ADAR1 Capital Management is now a beneficial owner, holding a 10% stake in the company. The filing indicates ADAR1 Capital Management owns 3,827,951 shares of common stock, along with pre-funded and regular warrants. The ownership event occurred on August 20, 2026, with the filing signed on August 24, 2026.

    Bitget•8/25/26•
    Neutral

    TENX Stock Draws Bullish Targets Ahead Of Trial Data

    Tenax Therapeutics (TENX) stock is trading up by 11.08% due to optimism surrounding its clinical progress, with bullish targets from analysts like Canaccord Genuity, which initiated coverage with a Buy rating and a $35 price target. The company is anticipating key trial data from its LEVEL trial for pulmonary hypertension in HFpEF at next month's European Society of Cardiology Congress. While some analysts have recalibrated their price targets, the general consensus points to significant upside potential if the trial data is positive, despite the inherent risks of biotech event plays.

    StocksToTrade•8/25/26•
    Somewhat-Bullish

    Tenax rises on over $1.8M insider buying (TENX:NASDAQ)

    Tenax Therapeutics (TENX) stock rose nearly 13% in premarket trading after Adar1 Capital Management, a major shareholder, purchased over $1.8 million worth of company shares. The cardiopulmonary drug developer saw this significant insider buying activity reported in a regulatory filing.

    Seeking Alpha•8/25/26•
    Bullish

    Adar1 Capital Management buys $1.8m of Tenax Therapeutics (TENX) shares

    Adar1 Capital Management, a significant owner and director of Tenax Therapeutics (TENX), recently purchased over $1.8 million worth of the company's common stock between August 20 and August 24, 2026. These purchases, made at weighted average prices ranging from $1.7542 to $1.7788 per share, increased Adar1's beneficial ownership to 4,853,818 shares. Despite the stock being down 84% year-to-date, InvestingPro analysis suggests it is undervalued and oversold, potentially influencing Adar1's investment, even as other analysts have downgraded TENX following disappointing Phase 3 trial results.

    Investing.com•8/25/26•
    Neutral

    Frequently Asked Questions About TENX

    Does TENX pay dividends?
    Tenax Therapeutics Inc (TENX) does not currently pay a regular dividend.
    What is TENX's market cap?
    Tenax Therapeutics Inc (TENX) has a market capitalization of $79.71M with a current stock price of $2.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In